Compare BCG & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | COCP |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 21.6M |
| IPO Year | 2025 | 2011 |
| Metric | BCG | COCP |
|---|---|---|
| Price | $1.15 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 24.4K | ★ 49.3K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | 54.65 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $187,144,000.00 | $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.56 | ★ N/A |
| Revenue Growth | ★ 10.80 | N/A |
| 52 Week Low | $1.11 | $0.76 |
| 52 Week High | $3.44 | $2.03 |
| Indicator | BCG | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 31.86 | 50.89 |
| Support Level | N/A | $1.14 |
| Resistance Level | $1.58 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 14.00 | 24.28 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.